January 9, 2017 12:00 AM ESTUpdated 12:27 AM
Deals

Savara jump­ing to the NYSE in re­verse merg­er with zom­bie biotech Mast

Arsalan Arif

Founder

Af­ter rais­ing $20 mil­lion and lay­ing out plans for a Phase III piv­otal tri­al of a re­for­mu­lat­ed an­tibi­ot­ic, Savara is get­ting the new year un­der­way …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times